세계의 유전성 암 검사 시장 - 업계 동향과 예측(-2029년)

Global hereditary cancer testing market is projected to register a CAGR of 12.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Global Hereditary Cancer Testing Market, By Test Type (Multi Panel Set, and Single-Site Genetic Test) Diagnosis Type (Biopsy, Imaging, Lab Tests) Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray) Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Vol-Hippel Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes) End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales) Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2029.

Rising incidence of hereditary cancer

Increased demand for non-invasive testing methods

Market Players:

The key market players for global hereditary cancer testing market are listed below:

Invitae Corporation

Illumina, Inc.

Natera, Inc.

CENTOGENE N.V.

4baseCare

Biocartis

Fulgent Genetics

Ambry Genetics

BioReference

PerkinElmer Inc.

LifeLabs

Abbott

BIO-HELIX

Cepheid

Eurofins Scientific

TABLE OF CONTENTS

1 INTRODUCTION 32

• 1.1 OBJECTIVES OF THE STUDY 32
• 1.2 MARKET DEFINITION 32
• 1.3 OVERVIEW OF THE GLOBAL HEREDITARY CANCER TESTING MARKET 32
• 1.4 CURRENCY AND PRICING 34
• 1.5 LIMITATIONS 34
• 1.6 MARKETS COVERED 35

2 MARKET SEGMENTATION 38

• 2.1 MARKETS COVERED 38
• 2.2 GEOGRAPHICAL SCOPE 39
• 2.3 YEARS CONSIDERED FOR THE STUDY 40
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 41
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
• 2.6 MULTIVARIATE MODELLING 45
• 2.7 MARKET END USER COVERAGE GRID 46
• 2.8 SOURCE LIFELINE CURVE 47
• 2.9 DBMR MARKET POSITION GRID 48
• 2.10 VENDOR SHARE ANALYSIS 50
• 2.11 SECONDARY SOURCES 51
• 2.12 ASSUMPTIONS 51

3 EXECUTIVE SUMMARY 52

4 PREMIUM INSIGHT 56

• 4.1 PESTEL ANALYSIS 58
• 4.2 PORTER'S FIVE FORCES 59

5 GLOBAL HEREDITARY CANCER TESTING MARKET: REGULATIONS 60

6 MARKET OVERVIEW 65

• 6.1 DRIVERS 67
  • 6.1.1 RISING INCIDENCE OF HEREDITARY CANCER 67
  • 6.1.2 INCREASE IN THE GERIATRIC POPULATION 67
  • 6.1.3 RISING HEALTHCARE SPENDING 68
  • 6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING 68
• 6.2 RESTRAINTS 69
  • 6.2.1 HIGH COST OF HEREDITARY CANCER TESTING 69
  • 6.2.2 LACK OF SKILLED PROFESSIONALS 70
• 6.3 OPPORTUNITIES 70
  • 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 70
  • 6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 71
  • 6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 72
  • 6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES 72
• 6.4 CHALLENGES 73
  • 6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING 73
  • 6.4.2 RISING COMPETITION AMONG MARKET PLAYERS 74

7 GLOBAL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE 75

• 7.1 OVERVIEW 76
• 7.2 MULTI PANEL TEST 79
• 7.3 SINGLE-SITE GENETIC TEST 79

8 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE 80

• 8.1 OVERVIEW 81
• 8.2 BIOPSY 84
  • 8.2.1 NEEDLE BIOPSIES 84
  • 8.2.2 ENDOSCOPIC BIOPSIES 84
  • 8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY 85
  • 8.2.4 LAPAROTOMY AND THORACOTOMY 85
  • 8.2.5 OTHERS 85
• 8.3 IMAGING 85
  • 8.3.1 MAGNETIC RESONANCE IMAGING (MRI) 86
  • 8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN 86
  • 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 86
  • 8.3.4 NUCLEAR SCAN 86
  • 8.3.5 ULTRASOUND 86
  • 8.3.6 X-RAYS 86
• 8.4 LAB TESTS 87
  • 8.4.1 BLOOD 87
  • 8.4.2 URINE 87
  • 8.4.3 OTHERS 87

9 GLOBAL HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY 88

• 9.1 OVERVIEW 89
• 9.2 POLYMERASE CHAIN REACTION (PCR) 92
• 9.3 SEQUENCING 92
• 9.4 MICRO ARRAY 93

10 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE 94

• 10.1 OVERVIEW 95
• 10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME 98
• 10.3 COWDEN SYNDROME 98
• 10.4 LYNCH SYNDROME 99
• 10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME 99
• 10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 100
• 10.7 LI-FRAUMENI SYNDROME 100
• 10.8 VON HIPPEL-LINDAU DISEASE 101
• 10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME 101

11 GLOBAL HEREDITARY CANCER TESTING MARKET, BY END USER 102

• 11.1 OVERVIEW 103
• 11.2 HOSPITALS 106
• 11.3 CLINICS 106
• 11.4 DIAGNOSTIC CENTERS 107
• 11.5 RADIOLOGY CENTERS 107
• 11.6 LABORATORIES 108
• 11.7 OTHERS 108

12 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL 109

• 12.1 OVERVIEW 110
• 12.2 DIRECT TENDER 113
• 12.3 RETAIL SALES 113

13 GLOBAL HEREDITARY CANCER TESTING MARKET, BY REGION 114

• 13.1 OVERVIEW 115
• 13.2 ASIA-PACIFIC 120
  • 13.2.1 CHINA 128
  • 13.2.2 JAPAN 132
  • 13.2.3 SOUTH KOREA 136
  • 13.2.4 INDIA 140
  • 13.2.5 AUSTRALIA 144
  • 13.2.6 SINGAPORE 148
  • 13.2.7 THAILAND 152
  • 13.2.8 MALAYSIA 156
  • 13.2.9 INDONESIA 160
  • 13.2.10 PHILIPPINES 164
  • 13.2.11 REST OF ASIA-PACIFIC 168
• 13.3 NORTH AMERICA 169
  • 13.3.1 U.S. 176
  • 13.3.2 CANADA 180
  • 13.3.3 MEXICO 184
• 13.4 EUROPE 188
  • 13.4.1 GERMANY 196
  • 13.4.2 FRANCE 200
  • 13.4.3 U.K. 204
  • 13.4.4 RUSSIA 208
  • 13.4.5 ITALY 212
  • 13.4.6 SPAIN 216
  • 13.4.7 TURKEY 220
  • 13.4.8 NETHERLANDS 224
  • 13.4.9 SWITZERLAND 228
  • 13.4.10 BELGIUM 232
  • 13.4.11 REST OF EUROPE 236
• 13.5 SOUTH AMERICA 237
  • 13.5.1 BRAZIL 244
  • 13.5.2 ARGENTINA 248
  • 13.5.3 REST OF SOUTH AMERICA 252
• 13.6 MIDDLE EAST AND AFRICA 253
  • 13.6.1 SOUTH AFRICA 261
  • 13.6.2 SAUDI ARABIA 265
  • 13.6.3 U.A.E. 269
  • 13.6.4 EGYPT 273
  • 13.6.5 ISRAEL 277
  • 13.6.6 REST OF THE MIDDLE EAST AND AFRICA 281

14 GLOBAL HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE 282

• 14.1 COMPANY SHARE ANALYSIS: GLOBAL 282
• 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 283
• 14.3 COMPANY SHARE ANALYSIS: EUROPE 284
• 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 285

15 SWOT ANALYSIS 286

16 COMPANY PROFILE 287

• 16.1 ABBOTT 287
  • 16.1.1 COMPANY SNAPSHOT 287
  • 16.1.2 REVENUE ANALYSIS 287
  • 16.1.3 COMPANY SHARE ANALYSIS 288
  • 16.1.4 PRODUCT PORTFOLIO 288
  • 16.1.5 RECENT DEVELOPMENTS 288
• 16.2 ILLUMINA, INC. (2021) 289
  • 16.2.1 COMPANY SNAPSHOT 289
  • 16.2.2 REVENUE ANALYSIS 289
  • 16.2.3 COMPANY SHARE ANALYSIS 290
  • 16.2.4 PRODUCT PORTFOLIO 290
  • 16.2.5 RECENT DEVELOPMENTS 291
• 16.3 PERKINELMER INC. (2021) 292
  • 16.3.1 COMPANY SNAPSHOT 292
  • 16.3.2 REVENUE ANALYSIS 292
  • 16.3.3 COMPANY SHARE ANALYSIS 293
  • 16.3.4 PRODUCT PORTFOLIO 293
  • 16.3.5 RECENT DEVELOPMENTS 293
• 16.4 LIFELABS GENETICS 294
  • 16.4.1 COMPANY SNAPSHOT 294
  • 16.4.2 COMPANY SHARE ANALYSIS 294
  • 16.4.3 PRODUCT PORTFOLIO 295
  • 16.4.4 RECENT DEVELOPMENTS 295
• 16.5 EUROFINS SCIENTIFIC (2021) 296
  • 16.5.1 COMPANY SNAPSHOT 296
  • 16.5.2 REVENUE ANALYSIS 296
  • 16.5.3 COMPANY SHARE ANALYSIS 297
  • 16.5.4 PRODUCT PORTFOLIO 297
  • 16.5.5 RECENT DEVELOPMENT 297
• 16.6 AMBRY GENETICS 298
  • 16.6.1 COMPANY SNAPSHOT 298
  • 16.6.2 REVENUE ANALYSIS 298
  • 16.6.3 PRODUCT PORTFOLIO 299
  • 16.6.4 RECENT DEVELOPMENTS 299
• 16.7 BIOCARTIS 300
  • 16.7.1 COMPANY SNAPSHOT 300
  • 16.7.2 REVENUE ANALYSIS 300
  • 16.7.3 PRODUCT PORTFOLIO 301
  • 16.7.4 RECENT DEVELOPMENTS 301
• 16.8 BIO-HELIX 302
  • 16.8.1 COMPANY SNAPSHOT 302
  • 16.8.2 PRODUCT PORTFOLIO 302
  • 16.8.3 RECENT DEVELOPMENTS 302
• 16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021) 303
  • 16.9.1 COMPANY SNAPSHOT 303
  • 16.9.2 REVENUE ANALYSIS 303
  • 16.9.3 PRODUCT PORTFOLIO 304
  • 16.9.4 RECENT DEVELOPMENT 304
• 16.10 CENTOGENE N.V. (2021) 305
  • 16.10.1 COMPANY SNAPSHOT 305
  • 16.10.2 REVENUE ANALYSIS 305
  • 16.10.3 PRODUCT PORTFOLIO 306
  • 16.10.4 RECENT DEVELOPMENT 306
• 16.11 CEPHEID 307
  • 16.11.1 COMPANY SNAPSHOT 307
  • 16.11.2 PRODUCT PORTFOLIO 307
  • 16.11.3 RECENT DEVELOPMENT 307
• 16.12 FULGENT GENETICS 308
  • 16.12.1 COMPANY SNAPSHOT 308
  • 16.12.2 REVENUE ANALYSIS 308
  • 16.12.3 PRODUCT PORTFOLIO 309
  • 16.12.4 RECENT DEVELOPMENT 309
• 16.13 INVITAE CORPORATION 310
  • 16.13.1 COMPANY SNAPSHOT 310
  • 16.13.2 REVENUE ANALYSIS 310
  • 16.13.3 PRODUCT PORTFOLIO 311
  • 16.13.4 RECENT DEVELOPMENT 311
• 16.14 NATERA, INC. (2021) 312
  • 16.14.1 COMPANY SNAPSHOT 312
  • 16.14.2 REVENUE ANALYSIS 312
  • 16.14.3 PRODUCT PORTFOLIO 313
  • 16.14.4 RECENT DEVELOPMENTS 313
• 16.15 4BASECARE. 315
  • 16.15.1 COMPANY SNAPSHOT 315
  • 16.15.2 PRODUCT PORTFOLIO 315
  • 16.15.3 RECENT DEVELOPMENTS 316

17 QUESTIONNAIRE 317

18 RELATED REPORTS 320